Royalty Pharma plc Class A Ordinary Shares

RPRXNASDAQ • USD
ThemeAsset Mgmt & Capital Mkts›Private Equity & Alternative Investments
56.31 USD
↗ 0.64 (1.15%)AT CLOSE (11:59 AM EDT)
58.03
↗ 1.72 (3.05%)
POST MARKET (AS OF 06:29 PM EDT)
Post Market
AS OF 06:29 PM EDT
58.03
↗ 1.72 (3.05%)
🔴Market: CLOSED

Royalty Pharma plc Class A Ordinary Shares (RPRX) is currently trading at $56.30. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". Notable factors include a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jul 15, 2026.

Open?$55.67
High?$56.32
Low?$54.95
Prev. Close?$55.67
Volume?2.7M
Avg. Volume?3.6M
VWAP?$55.89
Rel. Volume?0.77x
Bid / Ask
Bid?$55.06 × 200
Ask?$58.55 × 4.1K
Spread?$3.49
Midpoint?$56.81
Valuation & Ratios
Market Cap?25.0B
Shares Out?443.3M
Float?435.9M
Float %?98.3%
P/E Ratio?30.17
P/B Ratio?3.62
EPS?$1.87
Dividend?2.95%
Ex-Dividend?N/A
News
Profile
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Themes
Asset Management & Capital Markets›Private Equity & Alternative InvestmentsBiotech - Drug Development›Clinical-Stage PlatformsHealthcare - Oncology›Immunotherapy & Immuno-Oncology
Employees
100
Market Cap
24.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.royaltypharma.com
Listed
2020-06-16
Address
110 EAST 59TH STREET
NEW YORK, NY 10022
Phone: (212) 883-0200
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
40
Momentum?
73
Short Sent.?
79
Piotroski F-Score?4/9Mixed
Altman Z-Score?2.12Grey
Confidence?74%Moderate
Full Fundamental Analysis →
Short InterestLow
Short % of Float?2.85%Low
Short Interest?12.4M
Days to Cover?3.0
Free Float435.9M
Avg Daily Volume4.2M
Settlement Date2026-06-30
Financial Health
Current Ratio?2.66Strong
Quick Ratio?2.66Strong
Cash Ratio?1.09Strong
Debt/Equity?1.30Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
40/100
P/E?
Peers
100
S&P
33
30.2PRICEY▾
P/B?
Peers
100
S&P
48
3.62FAIR▾
P/S?
Peers
100
S&P
8
10.23HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
19
22.7HIGH▾
EV/Sales?
Peers
100
S&P
5
13.67HIGH▾
Returns & Efficiency
ROE?
Peers
50
S&P
43
12.0%STRONG▾
ROA?
Peers
50
S&P
38
4.2%FAIR▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$33.4B
Fundamentals ratios updated end of day
MarketsMoversWatchlist